Viridian Therapeutics (VRDN) experienced a powerful rally yesterday, with its stock price accelerating upwards. The biotech firm closed at $31.44, marking a significant 4.38% increase, or $1.32, from its open of $30.12. The stock traded within a range of $29.92 to $31.51, demonstrating robust activity with a volume of 4,019,100 shares. This surge pushed the companys market capitalization to $3,468,075,136, signaling renewed investor confidence.
This impressive daily performance appears to be a direct reaction to a cascade of overwhelmingly positive news. BofA Securities initiated coverage on Viridian Therapeutics with a buy rating and an ambitious $47.00 price target, signaling strong conviction in the companys future prospects. This analyst endorsement was underpinned by Viridians stellar third-quarter 2026 results, which saw the company shatter revenue expectations, reporting $25.75 million against an anticipated $4.68 million. Furthermore, Viridian narrowed its adjusted loss to $0.81 per share, outperforming analyst estimates of a $1.02 loss.
The star of the show remains Lumvoa, Viridians treatment for thyroid eye disease (TED). The drug generated an impressive $25 million in third-quarter revenues, significantly exceeding consensus estimates, with over 100 patients already on therapy since its July launch. BofAs physician surveys project Lumvoa could capture more than 70% of the market share within two years, potentially reaching $1.3 billion in peak sales, positioning it as a formidable competitor to Amgens Tepezza. The anticipation of a permanent J-code effective January 1, 2027, is also expected to further accelerate Lumvoas uptake. This positive sentiment was echoed by other analysts, with Stifel raising its price target from $40.00 to $43.00, and several others, including HC Wainwright, Needham, Truist, and RBC, also increasing their targets.
From a broader perspective, this daily jump reinforces Viridian Therapeutics existing Stable uptrend. The trend analysis reveals a positive trajectory across the past month, with the earliest 15 trading days (Days 1-15) showing a regression slope of 2.8903% per day, and the most recent 15 trading days (Days 16-30) maintaining a positive, albeit slightly moderated, slope of 2.2607% per day. The overall 30-day window (Days 1-30) registered a healthy 2.7869% per day slope. While the delta classification indicates insufficient data to pinpoint a significant change in the rate of acceleration or deceleration between the two 15-day periods, the Stable uptrend classification for combined momentum clearly indicates sustained positive movement. Yesterdays powerful rally, fueled by strong earnings and bullish analyst coverage, acts as a potent confirmation of this underlying upward momentum, suggesting that the market is increasingly recognizing the commercial potential of Lumvoa and Viridians position in the competitive biotech landscape. Investors, much like seasoned generals, are observing whether this strong daily performance can solidify the companys strategic gains and propel it further into market leadership.